Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Ultra-low-dose Naloxone on Remifentanil-induced Postoperative Hyperalgesia - A Randomized Controlled Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients who are scheduled to undergo elective thyroidectomy~Exclusion Criteria:~* consent refusal, obesity, pregnancy, hx. of thyroid surgery, neurological disorders, psychiatric disorders, hx. of drug abuse or chronic use of opioids or sedative drugs, intake of any analgesic drug within 12h before surgery.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- group LR (Type: PLACEBO_COMPARATOR): low dose remifentanil (1 ng/ml of Ce) with normal saline infusion
- group HR (Type: ACTIVE_COMPARATOR): High dose remifentanil infusion (4ng/ml of Ce) with normal saline infusion
- group HR-N (Type: EXPERIMENTAL): remifentanil infusion at 4ng/ml of Ce with naloxone infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).